Order Article Reprints

Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, Oudomying N, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Avihingsanon Y, Assawasaksakul N, Buranapraditkun S, et al. Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study. Vaccines. 2022; 10(6):853. https://doi.org/10.3390/vaccines10060853

Assawasaksakul, Theerada, Tanat Lertussavavivat, Seelwan Sathitratanacheewin, Nont Oudomying, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Yingyos Avihingsanon, Nawaporn Assawasaksakul, Supranee Buranapraditkun, and et al. 2022. "Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study" Vaccines 10, no. 6: 853. https://doi.org/10.3390/vaccines10060853

Assawasaksakul, T., Lertussavavivat, T., Sathitratanacheewin, S., Oudomying, N., Vichaiwattana, P., Wanlapakorn, N., Poovorawan, Y., Avihingsanon, Y., Assawasaksakul, N., Buranapraditkun, S., & Kittanamongkolchai, W. (2022). Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study. Vaccines, 10(6), 853. https://doi.org/10.3390/vaccines10060853